Drug intelligence / Profile preview

BREXTEM-S

Development stage: Unknown
Lead developer: Brexogen
Modality: Small Molecules
Administration: Topical

Overview

BREXTEM-S is a topical liquid drug product developed by Brexogen Inc., a biotechnology company specializing in exosome-based therapies. The product contains niacinamide (Vitamin B3) as its primary active ingredient and is intended for external application to the skin. It is designed to be used as part of a two-component system, where the BREXTEM-S liquid is mixed with a companion lyophilized powder, BREXTEM, immediately prior to use. While niacinamide is recognized for its anti-inflammatory and skin-barrier-enhancing properties, BREXTEM-S is currently classified as an unapproved drug product by the FDA (assigned NDC code 83630-010-02). The product has not been evaluated by the FDA for safety or efficacy, and its labeling has not received official approval.

Brand names: BREXTEM-S

Beyond the preview

Go deeper on BREXTEM-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BREXTEM-S.

Explore the full profile